Search Results
Year | ID | Type | Category | Title | Authors |
---|
2023 | QOL28 | Poster | Quality of life and outcomes |
VA and National MS Society Partnership to Enhance Care for Veterans Living with MS |
Vicki Kowal, MA, LPCC, National MS Society, Albuquerque, NM, Jaimie Henry, MPA, VA MS Center of Excellence West, Portland, OR and Angela Young, MBA, VA MS Center of Excellence – East, Baltimore, MD |
2023 | QOL29 | Poster | Quality of life and outcomes |
Exercise Training and Health-Related Quality of Life in Adults with Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
Victoria A. Flores, PhD, Petra Šili?, BS, Noah G. DuBose, MS, Peixuan Zheng, PhD, Brenda Jeng, Ph.D and Robert W. Motl, PhD, Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL |
2023 | REH07 | Poster | Rehabilitation |
The Tablet Revolution: A Decade of Mobile Accessibility for People with Advanced MS |
Alexander Burnham, MS, CCC-SLP, MSCS, Rehabilitation Services, The Boston Home, Boston, MA; Communication Sciences and Disorders, Emerson College, Boston, MA |
2023 | REH10W | Poster | Rehabilitation |
Protocol Development: Assessing the Effectiveness of the Novel Ataxic Balance Crutch in the Multiple Sclerosis Population |
Erin M Faraclas, PT, DPT, PhD, MSCS and Mable Ye, PT/s, School of Physical Therapy, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA |
2023 | REH11 | Poster | Rehabilitation |
A Qualitative Exploration of the Rehabilitation Perceptions and Experiences of Persons with Early Multiple Sclerosis |
Gregory Brusola, PT, DPT, PhD, MSCS, Department of Physical Therapy, University of Texas Medical Branch at Galveston, Galveston, TX, Amber Armstead, OTR, DrPH, BCPR, Department of Occupational Therapy, University of Texas Medical Branch at Galveston, Galveston, TX and Carole Tucker, PT, PhD, Center for Health Promotion, Performance, and Rehabilitation Research (CHPPRR), University of Texas Medical Branch at Galveston, Galveston, TX |
2023 | REH12 | Poster | Rehabilitation |
Post-Discharge Telephone Coaching Doubles the Long-Term Beneficial Effects of Inpatient Multidisciplinary Rehabilitation! – the Danish MS Hospitals Rehabilitation Study. |
Michael Norgaard, MSc1, Finn Boesen, MD1, Anders G Skjerbaek, MRSc1, Ellen Jensen, MRsc2, Jeanne Hansen, BSN3, Peter V Rasmussen, Phd4, Thor Petersen, DMSc5 and Philipp Trénel, Phd6, (1)The Danish MS Hospitals, Haslev and Ry, Denmark, (2)The Danish MS Hospitals, Ry, Denmark, (3)The Danish MS Hospitals, Haslev, Denmark, (4)Aarhus University Hospital, Aarhus, Denmark, (5)Aarhus University Hospital, Sønderborg, Denmark, (6)Danish Technological Institute, Aarhus, Denmark |
2023 | REH13W | Poster | Rehabilitation |
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis |
Vicky L Chen, MD1,2, Andrea Hildebrand, BA3,4, Mark M Manago, PT, PhD5, Andrea Serdar, PT, NCS6 and Michelle H. Cameron, MD, PT, MCR1,2, (1)Neurology, Oregon Health & Science University, Portland, OR, (2)Neurology, VA Portland Health Care System, Portland, OR, (3)Biostatistics & Design Program, Oregon Health & Science University, Portland, OR, (4)Neurology, Portland VA Medical Center, Portland, OR, (5)Department of Physical Medicine and Rehabilitation, University of Colorado Anschutz Medical Campus, Aurora, CO, (6)OP Rehabilitation, Oregon Health & Science University, Portland, OR |
2023 | REH14 | Poster | Rehabilitation |
Attention, Walking Speed, and Automaticity during Gait in Adults with and without Multiple Sclerosis |
Myeongjin Bae, M.S., Michael Vannostrand, M.S. and Susan Kasser, Ph.D., Rehabilitation and Movement Science, University of Vermont, Burlington, VT |
2023 | REH15 | Poster | Rehabilitation |
Systematic Review and Meta-Analysis of Sedentary Behavior in Persons with Multiple Sclerosis |
Peixuan Zheng, PhD, Sydney R. DeJonge, MS, Victoria A. Flores, PhD, Brenda Jeng, Ph.D and Robert W. Motl, PhD, Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL |
2023 | REH16 | Poster | Rehabilitation |
Occupational Therapy’s Role in Supporting College Students with Multiple Sclerosis: A Case Study |
Rebecca Cunningham, OTD, OTR/L, MSCS and Hilary Stanek, MA, OTR/L, Chan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA |
2023 | REH17 | Poster | Rehabilitation |
Influence of Exercise on the Longevity Protein Alpha-Klotho in Multiple Sclerosis |
Sarah B Simmons, MD, PhD1, Alexis Skolaris, BA2, Gabrielle M Mey, PhD Candidate3, Tara M DeSilva, PhD4 and Susan M Linder, PT, DPT, PhD2, (1)Rehabilitation Medicine, University of Washington, Seattle, WA, (2)Department of Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, OH, (3)Cleveland Clinic, Cleveland, OH, (4)Neurosciences, Cleveland Clinic, Cleveland, OH |
2023 | REH18 | Poster | Rehabilitation |
Aerobic Cycling Improves Gait Velocity and Reduces Physical Fatigue in Persons with MS |
Tori M Fricker, BS1,2, Kristen Chew, BS2,3, Donayja Harris, BS2, Sarah Simmons, MD, PhD4, Alexis Skolaris, BA2, Yadi Li, MEd5, Brittany Lapin, PhD5, Francois Bethoux, MD2 and Susan M Linder, PT, DPT, PhD2, (1)Ohio University Heritage College of Osteopathic Medicine, Athens, OH, (2)Department of Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, OH, (3)Ohio University Heritage College of Osteopathic Medicine, Cleveland, OH, (4)Mellen Center, Cleveland Clinic, Cleveland, OH, (5)Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH |
2023 | REH19 | Poster | Rehabilitation |
Differential Neuromuscular Response to Functional Electrical Stimulation (FES) Cycling and Isolated Electrical Stimulation (iES) Strategies in People with Multiple Sclerosis with Mobility Impairment. |
Brad Willingham, PhD, Joy Williams, PT, DPT and Deborah Backus, PT, PhD, Crawford Research Institute, Shepherd Center, Atlanta, GA |
2023 | REH20 | Poster | Rehabilitation |
Pilates+4MS: Evaluating the Impact of Seated Pilates on Functional Outcomes Among Those with Mild, Moderate, and Severe MS Impairment |
Brynn Adamson, PhD1, Layla Almasri, BS1, Meghann Koppele Duffy, MS, CSCS2, Stacy Kirkpatrick, BS3, Keston Lindsay, PhD4 and Manuel E Hernandez, PhD5, (1)Health Sciences, University of Colorado Colorado Springs, Colorado Springs, CO, (2)The Neuro Studio, Washington DC, DC, (3)Normal, IL, (4)Human Physiology and Nutrition, University of Colorado Colorado Springs, Colorado Springs, CO, (5)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL |
2023 | REH21 | Poster | Rehabilitation |
Results of the MOVE MS Program: A Feasibility Study on Group Exercise for Individuals with Multiple Sclerosis |
Brynn Adamson, PhD1, Nic Wyatt, BS2, Latashia Key, MS3, Carrena Boone, BS1 and Robert W. Motl, PhD4, (1)Health Sciences, University of Colorado Colorado Springs, Colorado Springs, CO, (2)Kinesiology and Community Health, University of Illinois at Urbana Champaign, Urbana, IL, (3)Recreation, Sport and Tourism, University of Illinois at Urbana–Champaign, Urbana, IL, (4)Kinesiology and Nutrition, University of Illinois Chicago, Chicago, IL |
2023 | REH22 | Poster | Rehabilitation |
Mixed-Methods Approach to Foot-Drop Device Selection in Multiple Sclerosis: An Exploratory Study |
Jennifer N Bartloff, DPT, NCS, MS1, K. Heidi Fehr, .1, Yisen Wang, .1, Katherine Konieczka, .2, Julia Mastej, .2, Evan Cohen, PT, MA, PhD, NCS3 and Peter Adamczyk, PhD1, (1)Mechanical Engineering, University of Wisconsin, Madison, WI, (2)Biomedical Engineering, University of Wisconsin, Madison, WI, (3)Physical Therapy, Arcadia University, Glenside, PA |
2023 | REH23 | Poster | Rehabilitation |
A 12-Week Intensive Aerobic Cycling Intervention Reduces Fatigue and Pain in Persons with MS |
Alexis Skolaris, BA1, Kristen Chew, BS1, Tori M Fricker, BS1, Donayja Harris, BS1, Sarah Simmons, MD, PhD2, Yadi Li, MEd3, Brittany Lapin, PhD3, Francois Bethoux, MD4 and Susan M Linder, PT, DPT, PhD1, (1)Department of Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, OH, (2)Mellen Center, Cleveland Clinic, Cleveland, OH, (3)Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, (4)Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH |
2023 | REH24 | Poster | Rehabilitation |
Appraising Fall Risk in Adults with Multiple Sclerosis Using Novel, Ecologically Valid Mobility Assessments: The Bridge to Understanding Real-World Ambulation |
Michael VanNostrand, MS, Myeongjin Bae, M.S. and Susan Kasser, Ph.D., Rehabilitation and Movement Science, University of Vermont, Burlington, VT |
2023 | SYM01 | Poster | Symptom management |
Movement Disorders in MS: Prevalence, Anatomical Generators, and Relation to Relapse |
Hannah Kelly, BS1, Mohamed Elkasaby, MD1,2, Alexander Wang, MD1,2 and Hesham Abboud, MD, PhD1,3, (1)Case Western Reserve University School of Medicine, Cleveland, OH, (2)University Hospitals Cleveland Medical Center, Cleveland, OH, (3)Multiple Sclerosis and Neuroimmunology Program, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH |
2023 | SYM02 | Poster | Symptom management |
Classification of Pain and Its Relationship to Depression and Fatigue in Multiple Sclerosis |
Mitra Rouhani, PT, MS1, Marie K Hoeger Bement, PT, PhD1, Sandra Hunter, PhD1, Ahmed Z Obeidat, MD, PhD2, Kathleen M Zackowski, PhD, OTR3 and Alexander V Ng, PhD1, (1)Marquette University, Milwaukee, WI, (2)Neurology, Medical College of Wisconsin, Milwaukee, WI, (3)National Multiple Sclerosis Society, New York, NY |
2023 | SYM03W | Poster | Symptom management |
Solriamfetol As a Novel Treatment for Fatigue and Excessive Daytime Sleepiness in Patients with Multiple Sclerosis |
Samantha N Roman, MD and Bardia Nourbakhsh, MD, MAS, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD |
2023 | SYM04 | Poster | Symptom management |
Neural Effects of Fatigue on Cognition in Relapsing Multiple Sclerosis Detected By Magnetoencephalography: Towards an Imaging Biomarker. |
Anza B Memon, M.D1,2,3, Mouhamad Hammami, PhD student4, Lonni Schultz, PhD5 and Susan M Bowyer, PhD3,6, (1)2799 W Grand Blvd, 2799 W Grand Blvd, detroit, MI, (2)Neurology, Wayne State University, School of Medicine, Detroit, MI, (3)Neurology, Henry Ford Health, Detroit, MI, (4)4. Oakland University, Rochester Hills, MI, (5)Public Health Science, Henry Ford Health System, Detroit, MI, (6)Oakland University, Rochester Hills, MI |
2022 | DMT01 | Platform/Oral | Disease Modifying Therapies |
Treatment-Emergent COVID-19 in Ozanimod Multiple Sclerosis and Ulcerative Colitis Clinical Trials |
Bruce A.C. Cree, MD, PhD1, Ryan C. Ungaro, MD2, Jean-Frederic Colombel, MD2, Corey A. Siegel, MD, MS3, James K. Sheffield, MD4, John Vaile, PharmD4, Harris A. Ahmad, MD4, Ashwini Pai, MD4, Shabana Ather, MD4, Lorna Charles, MD4, AnnKatrin Petersen, MD4, Chun-Yen Cheng, PhD4, Sonia Afsari, MD4 and Krzysztof W. Selmaj, MD5, (1)Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)Icahn School of Medicine at Mount Sinai, New York, NY, (3)Dartmouth-Hitchcock Medical Center, Lebanon, NH, (4)Bristol Myers Squibb, Princeton, NJ, (5)Center for Neurology, ?ód?, Poland, and Department of Neurology, University of Warmia & Mazury, Olsztyn, Poland |
2022 | DMT02 | Platform/Oral | Disease Modifying Therapies |
Safety and Efficacy of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis over 2.5 Years of the Open-Label Extension to a Phase II Trial |
Xavier Montalban, MD PhD1, Jerry S Wolinsky, MD2, Douglas L Arnold, MD3,4, Martin S Weber, MD5, Ivan Staikov, MD PhD6, Karolina Piasecka-Stryczynska, PhD7, Davorka Tomic, PhD8, Emily C Martin, PhD9, Kristina H Holmberg, PhD9 and Hans Guehring, MD10, (1)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, (2)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, (3)Montreal Neurological Institute, McGill University, Montréal, QC, Canada, (4)NeuroRx Research, Montréal, QC, Canada, (5)Institute of Neuropathology and Department of Neurology, University Medical Center, University of Göttingen, Göttingen, Germany, (6)Department of Neurology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria, (7)Department of Neurology and Cerebrovascular Diseases, Pozna? University of Medical Sciences, Pozna?, Poland, (8)Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, (9)EMD Serono, Billerica, MA, (10)The healthcare business of Merck KGaA, Darmstadt, Germany |
2022 | DMT03 | Platform/Oral | Disease Modifying Therapies |
Reduced Disease Progression with Ublituximab Vs Teriflunomide in the Phase 3 Ultimate I and II Studies in Relapsing Multiple Sclerosis |
Enrique Alvarez, MD, PhD, University of Colorado, Aurora, CO, Lawrence Steinman, MD, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, CA, Edward J Fox, MD, PhD, Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, Round Rock, TX, Hans-Peter Hartung, MD, Heinrich Heine University, Dusseldorf, Germany; Brain and Mind Centre, University of Sydney, Sydney, Australia; Department of Neurology, Medical University of Vienna, Vienna, Austria; Department of Neurology, Palacky University, Olomouc, Czech Republic, Peiqing Qian, MD, Swedish Medical Center, Seattle, WA, Sibyl Wray, MD, Hope Neurology, Knoxville, TN, Derrick Robertson, MD, University of South Florida, Tampa, FL, DeRen Huang, MD, PhD, Center for Multiple Sclerosis, Mount Carmel Health System, Westerville, OH, Krysztof Selmaj, MD, PhD, Center of Neurology, Lodz, Poland; Department of Neurology, University of Warmia & Mazury, Olsztyn, Poland, Daniel Wynn, MD, Consultants in Neurology MS Center, Northbrook, IL, Lily Lee, PhD, TG Therapeutics, New York, NY and Bruce A Cree, MD, PhD, MAS, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA |
2022 | DMT04 | Platform/Oral | Disease Modifying Therapies |
Longer-Term Safety of Ofatumumab in Patients with Relapsing Multiple Sclerosis |
Jacqueline A Nicholas, MD, MPH1, Stephen L Hauser, PhD2, Anne H Cross, MD3, Kevin Winthrop, MD, MPH4, Heinz Wiendl, MD, MPH5, Sven G Meuth, MD, PhD6, Paul S Giacomini, MD7, Francesco Sacca, MD8, Ronald Zielman, MD, PhD9, Xixi Hu, PhD10, Ayan Das Gupta, Msc11, Roseanne Sullivan, PharmD10, Virginia DeLas Heras, MD12, Wendy Su, PhD10 and Ludwig Kappos, MD13, (1)OhioHealth Multiple Sclerosis Center, Columbus, OH, (2)UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, (3)Washington University School of Medicine, Saint Louis, MO, (4)Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, (5)University of Muenster, Muenster, Germany, (6)Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, (7)Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada, (8)NSRO Department, University “Federico II” of Naples, Naples, Italy, (9)Novartis Pharma B.V., Amsterdam, Netherlands, (10)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (11)Novartis Healthcare Pvt. Ltd, Hyderabad, India, (12)Novartis Pharma AG, Basel, Switzerland, (13)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland |
2022 | DMT05 | Platform/Oral | Disease Modifying Therapies |
Benefits of Repeated Confirmed Disability Progressions Analyses in MS Clinical Trials: A Case Study Using the Opera and Oratorio Trials and Their Open-Label Extensions |
Jerry S Wolinsky, MD1, Hans-Peter Hartung, MD2,3, Stephen L. Hauser, MD4, Robert T. Naismith, MD5, Hans-Martin Schneble, MD6, Ben Townsend, PhD6, Qing Wang, PhD6 and Ludwig Kappos, PhD7, (1)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, (2)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, (3)Brain and Mind Centre, University of Sydney, Sydney, Australia, (4)UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (5)Washington University School of Medicine, St. Louis, MO, (6)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (7)Research Center for Clinical Neuroimmunology and Neuroscience, University Hospital Basel, University of Basel, Basel, Switzerland |
2022 | DMT06 | Platform/Oral | Disease Modifying Therapies |
Perceptions and Discussions on the Use of Disease-Modifying Therapies during Family Planning in Women with Multiple Sclerosis |
Riley Bove, MD1, Noemi Pasquarelli, MSc, PhD2, Marina Gafarova, MD, PhD3, Christine Eighteen, MBA2, Natalie Joschko, PhD4, Corey Mandel, PhD5 and Ruth Dobson, PhD, FRCP6, (1)Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (3)Roche Moscow JSC, Moscow, Russian Federation, (4)Roche Pharma AG, Grenzach-Wyhlen, Germany, (5)Genentech, Inc., San Francisco, CA, (6)Preventative Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom |
2022 | DXM01 | Platform/Oral | Disease Management I |
A Novel Educational Program for Relationship-Centered Shared Decision Making in Multiple Sclerosis, with a Focus on Cognition |
Annette F Okai, MD1, Mitzi J Williams, MD2, Megan Weigel, DNP3, Dana Jones, NP4, Steve Cole, MD5, Richard Frankel, PhD6, Amanda Montague, EdM7, Barry Hendin, MD8, Jennifer Reardon, MD9, Shawn Keogan, MD9, Jean-Pierre Morello, MD9 and Leorah Freeman, MD, PhD10, (1)North Texas Institute of Neurology & Headache, Plano, TX, (2)Joi Life Wellness, MS Neurology Center, Smyrna, GA, (3)First Coast Integrative Medicine, Jacksonville, FL, (4)Holy Name Medical Center, Teaneck, NJ, (5)Stony Brook University School of Medicine, Stony Brook, NY, (6)Indiana University of Medicine, Indianapolis, IN, (7)Multiple Sclerosis Association of America, Cherry Hill, NJ, (8)Center for Neurology and Spine, Phoenix, AZ, (9)Bristol Myers Squibb, Princeton, NJ, (10)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX |
2022 | DXM02 | Platform/Oral | Disease Management I |
Recognition and Awareness of Spasticity in Multiple Sclerosis – Optimizing the Patient/Clinical Dialogue – SEEN-MSS Survey |
Barry Hendin, MD1, Ben W Thrower, MD2, Scott D. Newsome, DO, MSCS, FAAN, FANA3, Robert Chinnapongse, MD4, Sherry Danese, BS, MBA5 and Jenifer Patterson, ARNP, MSCN4, (1)Center for Neurology and Spine, Phoenix, AZ, (2)Crawford Research Institute, Shepherd Center, Atlanta, GA, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Jazz Pharmaceuticals, Carlsbad, CA, (5)Outcomes Insights, Agoura Hills, CA |
2022 | DXM03 | Platform/Oral | Disease Management I |
Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of MS Dmts: A Systematic Review |
Helen-Margaret O Onuorah, BA1, Odelin Charron, MSc, MSE1, Ethan Meltzer, MD1, Amanda Montague, EdM2, Alexis Crispino, BA2, Avery Largent, BA1, Ashlea Lucas, PA-C1 and Leorah Freeman, MD, PhD1, (1)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, (2)Multiple Sclerosis Association of America, Cherry Hill, NJ |
2022 | DXM04 | Platform/Oral | Disease Management I |
Spinal Movement Disorders in Transverse Myelitis, Nmosd, and Mogad |
Hesham Abboud, MD, PhD, Case Western Reserve School of Medicine – – Cleveland Heights, OH, Cleveland, OH; Multiple Sclerosis and Neuroimmunology Program, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, Rongyi Sun, BS, Case Western Reserve University School of Medicine, Cleveland, OH and Nikhil Modak, MD, University Hospitals of Cleveland, Cleveland, OH |
2022 | DXM05 | Platform/Oral | Disease Management I |
Demographics and Baseline Disease Characteristics of Black and Hispanic Patients with Multiple Sclerosis in the Chimes Trial |
Lilyana Amezcua, MD1, Annette F Okai, MD2, Anne H Cross, MD3, Nancy L Monson, PhD4, Ben W Thrower, MD5, Anthony T Reder, MD6, Jeffrey B English, MD7, Gregory F Wu, MD, PhD3, Evanthia Bernitsas, MD8, Shereen Yap, MSc9, Jugena Ndrio, PharmD9, Jinglan Pei, PhD9, Ellen M Mowry, MD, MCR10, Fabio Magrini, MD9 and Mitzi J Williams, MD11, (1)Keck School of Medicine, University of Southern California, Los Angeles, CA, (2)North Texas Institute of Neurology & Headache, Plano, TX, (3)Washington University School of Medicine, St. Louis, MO, (4)University of Texas Southwestern Medical Center, Dallas, TX, (5)Crawford Research Institute, Shepherd Center, Atlanta, GA, (6)University of Chicago Medicine, Chicago, IL, (7)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (8)Wayne State University School of Medicine, Detroit, MI, (9)Genentech, Inc., South San Francisco, CA, (10)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (11)Joi Life Wellness Group MS Center, Smyrna, GA |
2022 | DXM06 | Platform/Oral | Disease Management I |
The Relationship of Aspects of the Shared Decision Making Process and Vaccination Hesitancy in People with Multiple Sclerosis |
Olivia Kaczmarek, BS1, Ellie Teng, BS2, Avtej Sethi, MS2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD2, Myassar Zarif, MD2 and Mark Gudesblatt, MD3, (1)South Shore Neurologic Associates, Patchogue, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)South Shore Neurologic Associates, P.C., Islip, NY |
2022 | DXM07 | Platform/Oral | Disease Management II |
Characterizing Prospective Memory Errors and Their Neuropsychological Correlations in Persons with MS |
Caitlyn Nguyen, HS1, Sarah A Raskin, PhD2,3, Aaron P Turner, Ph.D. ABPP (RP)4,5,6, Zaenab Dhari, MD7,8, Lindsay O Neto, MPH7,8 and Elizabeth S Gromisch, PhD, MSCS8,9,10, (1)Trinity College, Hartford, CT, (2)Neuroscience Program, Trinity College, Hartford, CT, (3)Department of Psychology, Trinity College, Hartford, CT, (4)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (5)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (6)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (7)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (8)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (9)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (10)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT |
2022 | DXM08 | Platform/Oral | Disease Management II |
Comparative Diagnostic and Therapeutic Strategies Among General and Multiple Sclerosis (MS) Subspecialist Neurologists – Opportunities for Education |
Andrew J Solomon, MD1, Jiwon Oh, MD PhD FRCPC2, Robert A Bermel, MD3, Adnan Subei, DO4, Chloe Gianatasio, MS5, Natalie Goldberg, PhD5, Wendy Cerenzia, MS6 and Brian Moss, MBA5, (1)Neurological Sciences, University of Vermont College of Medicine, Burlington, VT, (2)Medicine, Division of Neurology, St. Michael’s Hospital, Univ of Toronto, Toronto, ON, Canada, (3)Mellen Center for MS, Cleveland Clinic, Cleveland, OH, (4)Neurology, Memorial Healthcare System, Hollywood, FL, (5)Efficient CME, Fort Lauderdale, FL, (6)CE Outcomes, LLC, Birmingham, AL |
2022 | DXM09 | Platform/Oral | Disease Management II |
COVID-19 Vaccination Intent and Uptake in People with MS: A Longitudinal Survey Study |
Odelin Charron, MSc, MSE1, Kenneth Onuorah, AS Candidate1, Helen-Margaret O Onuorah, BA1, Amanda Montague, EdM2, Alexis Crispino, BA2, Randa Hamden, PhD, MPH3, Trudy Krause, DrPH, MS3, Avery Largent, BA1, Ashlea Lucas, PA-C1, Ethan Meltzer, MD1 and Leorah Freeman, MD, PhD1, (1)Neurology, Dell Medical School, The University of Texas at Austin, Austin, TX, (2)Multiple Sclerosis Association of America, Cherry Hill, NJ, (3)Center for Healthcare Data, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX |
2022 | DXM10 | Platform/Oral | Disease Management II |
Predicting Satisfaction with Functioning in Psychosocial Life Areas for People with MS |
Louise C Palmer, MA1, Mark Sweatman, PhD2, James Krause, Ph.D.3, Melinda Jarnecke, BS4 and Deborah Backus, PT, PhD1, (1)Shepherd Center, Atlanta, GA, (2)Georgia Gwinnett College, Lawrenceville, GA, (3)Professor and Associate Dean for Research, Medical University of South Carolina, Columbia, SC, (4)Medical University of South Carolina, Charleston, SC |
2022 | DXM11 | Platform/Oral | Disease Management II |
Improving Measures of Atrophy, Black Holes and Lesions and Their Impact on Diagnosis and Care. |
Marek Podyma, PhD, Pixel Technology, Lodz, Poland and Malgorzata Siger, MD PhD, Neurology, Medical University of Lodz, Lodz, Poland |
2022 | DXM12 | Platform/Oral | Disease Management II |
Effects on Quality of Life, Disease Impact and Physical Activity of a Day Wellness Program for People Living with Multiple Sclerosis before and during the COVID-19 Pandemic. |
Tiffany Malone, MSW, MSCS1, John Schafer, MD2, Lacey Sayre, CNA1 and Brian Hutchinson, PT, MSCS3, (1)Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA, (2)Multiple Sclerosis Achievement Center, Citrus Heights, CA, (3)Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA |